Amanote Research
Register
Sign In
Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
Klinicheskaya Onkogematologiya/Clinical Oncohematology
- Russian Federation
doi 10.21320/2500-2139-2016-9-4-398-405
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Hematology
Date
December 13, 2016
Authors
EA Demina
Publisher
Practical Medicine Publishing House
Related search
Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma
Malignant tumours
Brentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Review
Critical Reviews in Oncology/Hematology
Gerontology
Geriatrics
Hematology
Oncology
Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation
Vestnik dermatologii i venerologii
Successful Outcomes of Brentuximab Vedotin Therapy in Recurrent/Refractory Cutaneous T-Cell Lymphomas: Two Case Reports
Immunopathology, Allergology, Infectology
The Experience of Using the Brentuximab Vedotin in the Treatment of Children and Young Adults With Primary Refractory Course and Relapses of Hodgkin's Lymphoma
Pediatric Hematology/Oncology and Immunopathology
Oncology
Pediatrics
Child Health
Allergy
Hematology
Perinatology
Immunology
Clinical Characteristics and Treatment Results of Pediatric Relapsed/Refractory Non-Hodgkin’s Lymphomas
Oncogematologiya
Oncology
Hematology
Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Annals of Hematology
Medicine
Hematology
Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma
Blood and Lymphatic Cancer: Targets and Therapy
Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report
Drugs in R and D
Pharmacology
